(Photo: Reuters)
The Department of Disease Control (DDC) has recently made headlines by setting aside a substantial budget of 21 million baht for the acquisition of 3,000 doses of the MVA-BN mpox vaccine from Denmark. Dr. Thongchai Keeratihattayakorn, the director-general of the DDC, shared more about this strategic move, emphasizing that these precious doses are expected to land in the country within four months and will be reserved strictly for high-risk groups.
Dr. Thongchai clarified, “The vaccination program is designed to control the spread of the disease, focusing only on those who fall within high-risk categories, based on stringent medical guidelines.” Hence, a blanket vaccination for the general populace isn’t on the agenda.
The high-risk groups are divided primarily into two categories. The first category comprises individuals who are at risk prior to exposure, such as disease control staff positioned at international airports, border health-check units, those in medical roles, and laboratory personnel. These brave souls are the front-liners against the threat.
On the other hand, the second group includes individuals who require post-exposure prophylaxis. This typically involves those who have had intimate or extended close contact with known mpox patients.
One notable aspect Dr. Thongchai touched upon was the unique legislation facilitating this endeavor. Due to the absence of commercial interest in importing the mpox vaccine within Thailand, the Disease Control Act grants the DDC the authority to import necessary vaccines and medications without needing the nod from the Food and Drug Administration. This ensures prompt action can be taken to counter health crises.
Interestingly, the MVA-BN vaccine is a modern adaptation of the historic smallpox vaccine. While it may not offer hundred-percent immunity against infection, it possesses the significant advantage of potentially reducing the severity of the disease. “However,” Dr. Thongchai advised, “maintaining safe practices like avoiding close contact with those suspected of infection is still the best prevention method.”
He further reassured citizens by stating that mpox generally doesn’t cause severe illness, except in individuals with severely compromised immune systems, notably those with HIV/Aids. To put things into perspective, all 13 mpox-related fatalities in Thailand were among patients living with HIV/Aids.
He also provided statistics to calm public fears, stating, “Since January 2022, we’ve recorded only 833 mpox cases nationwide, with a stark gender disparity—812 cases in men and only 21 in women.”
The reason behind this skewed distribution lies in the nature of the virus transmission—it predominantly spreads through prolonged close skin contact. Thus, men and sex workers are primarily affected, lessening the necessity for a widespread vaccination campaign.
In related news, it’s heartening to note that the first case of the mpox variant in the country has successfully recovered, a testament to the country’s healthcare resilience and expertise.
The future steps promise vigilant monitoring and calculated medical strategies that prioritize both public safety and practical resource allocation. This initiative marks a significant effort in containing potential health threats while ensuring that the nation’s most vulnerable populations receive the protection they critically need.
It’s fantastic that Thailand is taking proactive measures. Vaccinating high-risk groups makes perfect sense.
But what if the virus starts spreading uncontrollably? Shouldn’t we consider vaccinating more people?
I get your concern, but blanket vaccination is costly and unnecessary for now. Prioritizing high-risk groups is the smart move.
Agreed, it’s better to be cautious. Resources aren’t unlimited, after all.
This is another example of government waste. 3,000 doses for a disease that’s not even widespread?
It’s about being prepared. Better to have the vaccine and not need it, than the other way around.
Absolutely, this move is a textbook example of preventive healthcare. Imagine the resources needed if an outbreak happens!
I still think it’s overkill. Taxpayer money should go to more pressing issues.
How come only high-risk groups are considered? What about the general populace leaving home every day?
High-risk groups are on the front lines; they need protection first. The general populace can avoid unnecessary contact.
It feels like a gamble to me. What if things change suddenly?
Protocols can adapt as situations evolve. The key is flexibility.
The virus affects mainly men? Why is that?
It spreads through prolonged skin contact, often in close-knit communities. Sadly, that’s why sex workers are more at risk.
Seriously? It’s 2024 and we are still having gender-specific viruses?
Dr. Thongchai’s emphasis on safe practices is critical. Vaccines are great, but we shouldn’t forget basic hygiene.
Is there any other country following a similar strategy? Or is Thailand going solo here?
Other countries are taking similar steps with high-risk groups. It’s a globally accepted practice.
The decision to bypass the FDA is risky. How can we ensure the safety of these vaccines?
The Disease Control Act allows for quicker response in emergencies. The vaccine’s safety is still thoroughly evaluated.
Still, there’s always a margin for error. Should international authorities oversee this?
Only 833 cases since January 2022? The fear seems exaggerated to me.
833 cases can still cause significant harm if left unchecked.
Prevention is better than cure. It’s great that we’re acting early.
Why is it taking four months to get the vaccines? Shouldn’t urgent measures be quicker?
Logistics and bureaucracy, unfortunately. Even fast-tracked processes take time.
13 deaths all among HIV/Aids patients? This highlights a bigger issue within our healthcare system.
We definitely need better care for immunocompromised people. The virus just exposes existing weaknesses.
This feels like fear-mongering. The disease isn’t even that severe.
Maybe, but better to be safe than sorry. Ignoring it would be negligent.
What happens if the virus mutates? Will these vaccines still be effective?
That’s an ongoing challenge for all vaccines, but it doesn’t mean we shouldn’t start somewhere.
True, but continuous research is crucial. Staying ahead of the curve is key.
Why Denmark? Aren’t there more local options available?
Sometimes specific vaccines are produced only in certain places. It’s about quality, not just location.
Fair enough, but we should still aim for more self-reliance in future.
Any side effects reported with this MVA-BN vaccine?
It’s generally considered safe, with mild side effects like soreness or fatigue being the most common.
I appreciate the emphasis on preventing spread through safe practices. Vaccines alone aren’t enough.
Ultimately, this move highlights global interconnectedness. What happens in one country affects us all.